AFP and hepatocellular carcinoma: Such approach would have been particularly useful in patients with lesser drug efficacy (i.e., Case-8, Case-9 and Case-10), where the divergence of AFP measured levels from the model predicted values let hypothesize the selection and expansion of more aggressive HCC clones that could benefit from a second line treatment.